EPHA2 and neoplasm: Recently Lin et al. demonstrated that targeting EphA2 while concomitantly using conventional cytotoxic chemotherapy successfully decreased tumour growth in vivo at least in part by inducing tumour-associated endothelial cell apoptosis [53], supporting EphA2 as a therapeutic antiangiogenic target.